MephamT.B., CombesR.D., BallsM., BarbieriO., BlokhuisH.J., CostaP., CrillyR.E., de Cock BuningT., DelpireV.C., O'HareM.J., HoudebineL-M., van KreijlC.F., van der MeerM., ReinhardtC.A., WolfE. & van ZellerA-M. (1998). The use of transgenic animals in the European Union. The report and recommendations of ECVAM Workshop 28. ATLA26, 21–43.
SoulimanS., BlanquetS., BeysaacE. & CardotJ.M. (2006). A level A in vitro/in vivo correlation in fasted and fed states using different methods: Applied to solid immediate release oral dosage form. European Journal of Pharmaceutical Sciences27, 72–79.
4.
FarmerH., McCabeN., LordC.J., TuttA.N.J., JohnsonD.A., RichardsonT.B., SantarosaM., DillonK.J., HicksonI., KnightsC., MartinN.M.B., JacksonS.P., SmithG.C.M. & AshworthA. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, London434, 917–921.
